OncoMed to Present Clinical Data for Wnt Inhibitors at the ESMO 2016 Congress
29 sept. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present interim data from Phase 1b clinical trials of the company’s Wnt...
OncoMed Management to Present at Two Upcoming Investment Conferences
31 août 2016 16h10 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing...
OncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
23 août 2016 16h02 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals Announces Pricing of Public Offering of Common Stock
18 août 2016 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...